Arbutus Biopharma Corporation (ABUS) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Arbutus Provides 2025 Corporate and Financial Update

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in...

Form EFFECT - Notice of Effectiveness

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Believes Now Is the Logical Time for Arbutus to Pursue a License and Collaboration Agreement With a Strategic Partner and Explore All Options for...

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus”...

Form 8-K - Current report

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]